ISSN 2692-5877
DOI: 10.46998/IJCMCR.2024.46.001128

International Journal of
Clinical Studies & Medical Case Reports

Short Communication

Personalized, Targeted Cancer Therapies

Nemat Khansari*

Tehran University of Medical Sciences, School of Medicine, Department of Immunology, Tehran, Iran

***Corresponding author:** Nemat Khansari, Tehran University of Medical Sciences, School of Medicine, Department of Immunology, Tehran, Iran

Received: October 08, 2024 **Published:** November 06, 2024

Abstract

Personalized targeted cancer therapies represent a transformative approach in oncology, leveraging individual tumors' unique genetic and molecular characteristics to tailor treatment strategies. Rapid advancements in genomic technologies, such as microarray and sequencing, facilitate this approach, identifying specific biomarkers associated with various cancers. Biomarkers are crucial in developing and implementing personalized therapies, indicating biological processes, disease states, or responses to therapeutic interventions. The complexity of molecular alterations in tumors is a critical factor influencing the prognosis and treatment response in cancer patients. Integrating multi-omics approaches, such as genomics, transcriptomics, proteomics, and metabolomics, is invaluable in personalized medicine, leading to identifying novel biomarkers that can be targeted therapeutically. However, challenges remain in validating and implementing biomarkers in clinical practice, such as the heterogeneity of tumors, the dynamic nature of cancer evolution, and the potential for resistance mechanisms.

Personalized targeted cancer therapies represent a significant advancement in oncology, focusing on tailoring treatment strategies based on individual patient characteristics, mainly genetic and molecular profiles. This approach is grounded in the understanding that cancer is not a uniform disease but a collection of heterogeneous conditions that can vary significantly from one patient to another. The emergence of personalized medicine has been facilitated by rapid advancements in genomic technologies, including microarray and sequencing technologies, which have identified specific biomarkers associated with various cancers [1,2]. Biomarkers play a crucial role in developing and implementing personalized, targeted therapies. They indicate biological processes, disease states, or responses to therapeutic interventions. Identifying actionable biomarkers allows clinicians to predict which patients are most likely to benefit from specific treatments, thereby enhancing the efficacy of therapeutic regimens while minimizing unnecessary side effects [3,4]. For instance, in lung cancer, mutations in the Epidermal Growth Factor Receptor (EGFR) gene can guide targeted therapies such as tyrosine kinase inhibitors, which have shown improved outcomes compared to traditional chemotherapy [5,6]. The complexity of molecular alterations in tumors is a critical factor influencing the prognosis and treatment response in cancer patients. Studies have demonstrated that the presence of specific genetic mutations or changes can significantly impact the effectiveness of targeted therapies. For example, in pancreatic cancer, the identification of gene mutations such as KRAS and TP53 has been linked to poor prognosis and resistance to standard treatments [3]. This highlights the necessity of comprehensive molecular profiling to inform treatment decisions and optimize patient outcomes.

Furthermore, integrating multi-omics approaches, encompassing genomics, transcriptomics, proteomics, and metabolomics, is invaluable in personalized medicine. These methodologies facilitate a more comprehensive understanding of the tumor microenvironment and the molecular underpinnings of cancer, ultimately leading to the identification of novel biomarkers that can be targeted therapeutically [7,8]. For instance, circulating tumor DNA (ctDNA) as a biomarker has emerged as a promising strategy for monitoring treatment response and detecting minimal residual disease in various cancers, including breast and colorectal [9]. The clinical application of personalized, targeted therapies is exemplified by initiatives such as the National Cancer Institute's Molecular Analysis for Therapy Choice (NCI-MATCH) trial, which utilizes genomic sequencing to match patients with appropriate targeted therapies based on their tumor's molecular profile. This trial has demonstrated that many patients with actionable mutations can benefit from personalized treatment strategies, underscoring the potential of biomarker-driven approaches in improving clinical outcomes [6,10].

Developing novel therapeutic agents, including monoclonal antibodies and immune checkpoint inhibitors, has expanded oncologists' arsenal of targeted therapies [11,12]. Despite the promising advancements in personalized, targeted therapies, challenges remain in validating and implementing biomarkers

DOI: 10.46998/IJCMCR.2024.46.001128

in clinical practice. The heterogeneity of tumors, the dynamic nature of cancer evolution, and the potential for resistance mechanisms complicate the landscape of biomarker development [13,14]. For instance, while specific biomarkers may predict initial treatment responses, they may not account for subsequent resistance, necessitating ongoing research to identify additional predictive markers [15]. Moreover, integrating biomarkers into routine clinical practice requires robust clinical trial data to establish their efficacy and safety in diverse patient populations [16].

Conclusion

Personalized, targeted cancer therapies represent a paradigm shift in oncology, driven by identifying and applying biomarkers that inform treatment decisions. The ongoing research and development of novel biomarkers and advancements in genomic technologies are promising to enhance the precision of cancer therapies and improve patient outcomes. As the field continues to evolve, integrating multi-omics data and innovative therapeutic strategies will be essential in overcoming the challenges associated with cancer heterogeneity and treatment resistance.

References

1. Kamel HFM, Al-Amodi HS. Exploitation of gene expression and cancer biomarkers in paving the path to era of personalized medicine. Genomics, Proteomics &Amp; Bioinformatics, 2017; 15(4): 220-235. https://doi.org/10.1016/j.gpb.2016.11.005.
2. Gadade DD, Jha H, Kumar C, Khan F. Unlocking the power of precision medicine: exploring the role of bi-omarkers in cancer management. Future Journal of Pharmaceutical Sciences, 2024; 10(1). https://doi.org/10.1186/s43094-023-00573-2.
3. Regel I, Kong B, Bruns P, Michalski C, Kleeff J. Complexity of molecular alterations impacts pancreatic can-cer prognosis. World Journal of Gastrointestinal Oncology, 2013; 5(1): 1. https://doi.org/10.4251/wjgo.v5.i1.1.
4. Cerella C, Lorant A, Aquilano K, Diederich M. Editorial: next-generation cancer therapies based on a (r)evolution of the biomarker landscape. Frontiers in Pharmacology, 2022; 13. https://doi.org/10.3389/fphar.2022.861424.
5. K W, House L, W L, Cho WC. Personalized targeted therapy for lung cancer. International Journal of Molecu-lar Sciences, 2012; 13(9): 11471-11496. https://doi.org/10.3390/ijms130911471.
6. Garon EB, Abarca P, Strunck JL, Nameth D, Neumann CM, Wolf B, et al. Clinical trials in non-small cell lung cancer with biomarker-driven treatment allocation: ready or not, here we come. Critical Reviews in Oncogen-esis, 2015; 20(5-6): 339-347. https://doi.org/10.1615/critrevoncog.v20.i5-6.70.
7. Li K, Wang Q, Tang X, Akakuru OU, Li R, Wang Y, et al. Advances in prostate cancer biomarkers and probes. Cyborg and Bionic Systems, 2024; 5. https://doi.org/10.34133/cbsystems.0129.
8. Tănase C, Albulescu R, Neagu M. Proteomic approaches for biomarker panels in cancer. Journal of Immuno-assay and Immunochemistry, 2015; 37(1): 1-15. https://doi.org/10.1080/15321819.2015.1116009.
9. Duffy MJ, McDermott E, Crown J. Blood-based biomarkers in breast cancer: from proteins to circulating tu-mor cells to circulating tumor dna. Tumor Biology, 2018; 40(5): 101042831877616. https://doi.org/10.1177/1010428318776169
10. Garon EB, Abarca P, Strunck JL, Nameth D, Neumann CM, Wolf B, et al. Clinical trials in non-small cell lung cancer with biomarker-driven treatment allocation: ready or not, here we come. Critical Reviews in Oncogen-esis, 2015; 20(5-6): 339-347. https://doi.org/10.1615/critrevoncog.v20.i5-6.70.
11. Liu D. Cancer biomarkers for targeted therapy. Biomarker Research, 2019; 7(1). https://doi.org/10.1186/s40364-019-0178-7.
12. Butterfield LH. The society for immunotherapy of cancer biomarkers task force recommendations review. Seminars in Cancer Biology, 2018; 52: 12-15. https://doi.org/10.1016/j.semcancer.2017.09.006.
13. Duda DG. Abstract ia08: biomarkers of response and resistance to anti-angiogenic therapy. Molecular Cancer Therapeutics, 2015; 14(12_Supplement_1): IA08-IA08. https://doi.org/10.1158/1538-8514.tumang15-ia08.
14. Kelloff GJ, Sigman CC. Cancer biomarkers: selecting the right drug for the right patient. Nature Reviews Drug Discovery, 2012; 11(3): 201-214. https://doi.org/10.1038/nrd3651.
15. Figg WD, Newell DR. Pharmacologic biomarkers in the development of stratified cancer medicine. Clinical Cancer Research, 2014; 20(10): 2525-2529. https://doi.org/10.1158/1078-0432.ccr-14-0511.
16. Beckman RA, Chen C. Efficient, adaptive clinical validation of predictive biomarkers in cancer therapeutic development. Advances in Cancer Biomarkers, 2015; 81-90. https://doi.org/10.1007/978-94-017-7215-0_6.